GeneMatrix is contributing to human health through vaccine development.
GeneMatrix is focusing its capabilities on developing vaccines specialized for infectious diseases and cancer in accordance with the vision of ‘achieving vaccine sovereignty and entering the global market’. The focus of our research is to develop proprietary treatments for prevention of infectious diseases and to address cancer for which there is no cure. At the core of all these processes is GeneMatrix's R&D expertise in immunology, genetics, and advanced biotechnology.
GeneMatrix aims to leap forward to become a globally competitive vaccine development company, pursuing daily innovations through the following three key research activities:
Focus area: Vaccines
GeneMatrix researchers are focusing their capabilities on developing next-generation vaccines for the prevention and treatment of diseases based on their proprietary platform technology. New technologies are being applied, numerous groundbreaking attempts are being made, and a number of vaccine candidates are being researched and developed.
The current vaccine pipeline includes development of vaccines for the treatment of cervical cancer in the oncology field, as well as major infectious diseases such as hepatitis A, Japanese encephalitis, and coronavirus.
Specific areas of interest in Vaccine Research include:
- Infectious Disease
-
• Hepatitis A• Japanese encephalitis• Herpes zoster• COVID-19• Zika virus
- Oncology
- • Cervical cancer
Our Capabilities
GeneMatrix is developing vaccine candidates that effectively prevent and treat diseases and exerting its full competence in addressing intricate and complex challenges.
Vaccine development is an optimization process that identifies a correct target and improves the hit rate on the target based on an approach to the underlying cause of disease. Discovering a cure for a disease is challenging and requires a variety of specialized knowledge and skills to arrive at the optimal treatment.
GeneMatrix conducts intensive research by utilizing technology platforms necessary to develop new treatments, along with a fundamental approach to diseases based on extensive research data.
Partnership
GeneMatrix is maximizing its development capabilities by conducting joint research and development through strategic C&D (Connect & Development) with innovative domestic and foreign pharmaceutical companies, government agencies, and medical institutions. Our company is always open to communication with domestic and foreign industry, academia, companies, universities, and research institutes.
